

REAL WORLD EVIDENCE: CAN WE REALLY EXPECT IT TO HAVE MUCH INFLUENCE?

Keith Evans

InScience Communications

What is Real World Data and Evidence?

- “Data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials.”
 - Federal Food, Drug and Cosmetic Act Section 505F (b)
- “RWE is clinical evidence regarding the usage, and potential benefits or risks, of a medical product derived from analysis of RWD.”
 - CDRH. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration (FDA) Staff (CDRH Guidance)

RWE Strengths


- 85% of clinical interventions are not covered by guidelines
- It has many applications
 - Pre-development phase
 - Market access phase
 - Market usage phase
- RWE can cover diverse or specific sub-populations
- Easy to gather¹ and generalize from
- Its really not that new²
- We have used it successfully in healthcare already³

1. Department of Health (2005). *Chief Executive's report to the NHS: December 2005*.
http://webarchive.nationalarchives.gov.uk/20071204134909/http://www.dh.gov.uk/prod_consum_dh/idcplg?IdcService=GET_FILE&dID=11878&Rendition=Web
2. Gnanalingham MG, Robinson SG, Hawley DP, *et al* A 30 year perspective of the quality of evidence published in 25 clinical journals: Signs of change? *Postgraduate Medical Journal* 2006;82:397-399.
3. European Medicines Agency (2016). *EMA Annual Report*
www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2017/05/WC500227334.pdf

RWE Weaknesses

- The data
 - Quality
 - Bias
 - Ownership/Privacy
- Regulation
- 50+ years of RCTs
- 30+ years of the hierarchy of evidence

The Hierarchy of Evidence



RWE Weaknesses

- The data
 - Quality
 - Bias
 - Ownership/Privacy
- Regulation
- 50+ years of RCTs
- 30+ years of the hierarchy of evidence
- Lack of knowledge
 - “If you cannot explain this process to clinicians in a way that confirms its accuracy..you will find that, to them, such data has no value.”¹

1. Looney. Real-World Evidence: From Volume to Value. (2016) Pharmaceutical Executive Volume 36, Issue 10


Interactive Question 1

- The probability that a woman has breast cancer is 1% ("prevalence")
- If a woman has breast cancer, the probability that she tests positive is 90% ("sensitivity")
- If a woman does not have breast cancer, the probability that she nevertheless tests positive is 9% ("false alarm rate")

How many women who test positive actually have breast cancer?

- A. Nine in 10
- B. Eight in 10
- C. One in 10
- D. One in 100


Easier to understand?



How does pharma plan to measure success in using RWE?

- Number of publications
- Use in HTA
- Decreased use of external vendors
- Sales
- Clinical development activity
- Use in regulatory submissions
- Use in value-based contracting

Successful?



..or not?

- 6% of HTA decision making involved RWE¹
- ASCO/NCCN reject formal role for RWE in clinical guidelines. Few other guidelines incorporate RWE
- In a study of decision makers use of RWE evidence in the US²
 - 60% of respondents reported that RWE delivered information in diverse populations only ‘sometimes’
 - Not widely using in P&T decisions
 - 24% were confident in their ability to interpret results
 - 29% were aware of two recent RWE studies in JAMA and NEJM

1. Does real world evidence matter in Health Technology Assessments? <https://pharmaphorum.com/articles/does-real-world-evidence-matter-in-health-technology-assessments/>

2. Malone et al. Real World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies? (2018) Value in Health 21; 326-333.

What can we do to improve things?

- Short term
 - Data visualisation
 - Publish the protocol
 - Publish non-study materials on RWE
- Longer term
 - Forget the old ‘hierarchy of evidence’
 - We are looking to complement NOT compete
 - How RWE can be helpful
 - How we minimise bias